Led · Series B · May 2026

Founded in 2015 and led by CEO Sella Brosh, NVision develops quantum-enabled healthcare technologies based on engineering and controlling quantum properties of organic molecules. Its POLARIS platform enables real-time measurement of metabolism on standard MRI systems, and its Photonic Integrated Quantum Circuits (PIQC) platform supports its quantum computing efforts. The company raised $55M in a Series B (including a $17M EIB venture loan), bringing total funding to $120M. NVision plans to use the new funding to expand operations and further its development efforts. The firm positions its combined platforms to improve understanding of disease and support therapeutic development. Financially, the recent round added both equity and debt capital to the company’s balance sheet.

Participated · Series G · Mar 2026

Whoop builds wearable fitness and health trackers paired with a subscription service that captures user biometric and performance data. The company ships millions of hardware units globally while operating a recurring-revenue subscription model, which management says makes bookings the most useful operating metric. Whoop exited last year at a $1.1 billion bookings run rate, representing 103% year-over-year growth. It has now raised roughly $900 million in total capital since founding. The company is investing raised capital in hiring and talent, marketing and brand awareness, continued R&D, and accelerating international expansion. Whoop is also pursuing deeper health and medical capabilities, underscored by strategic participation from Abbott and Mayo Clinic in the latest round.

Participated · Series D · Aug 2025

SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

Led · Series C · Jun 2020

Bigfoot Biomedical is a Milpitas, California–based medical device company that develops therapy and telemedicine solutions for people with insulin-requiring Type 1 and Type 2 diabetes. Its lead product under development, the Bigfoot Unity System, is part of the Bigfoot Unity Diabetes Management Program and provides real-time dose-decision support for users on Multiple Daily Injection (MDI) therapy. Unity uses proprietary smart pen caps for basal and mealtime insulin dosing recommendations and integrates Abbott’s FreeStyle Libre glucose-sensing platform. The company plans to package Unity as a monthly subscription that includes pen caps, Abbott sensing technology, needles, a backup glucose meter, test strips, alcohol swabs and a mobile app, while insulin pens are obtained separately. Bigfoot also develops the Bigfoot Autonomy pump-based closed-loop automated insulin delivery system, which has received FDA Breakthrough Device designation and will require a pivotal trial and regulatory approvals. The company is led by CEO Jeffrey Brewer. Bigfoot Biomedical develops AI-driven diabetes solutions aimed at optimizing insulin dosing and delivery for people with insulin-requiring diabetes. Its product programs include Bigfoot Loop, an infusion pump–based closed-loop automated insulin delivery system, and Bigfoot Inject, a connected insulin pen decision‑support system for people on injection therapy. The company has an agreement with Abbott to integrate Abbott's FreeStyle Libre glucose‑sensing technology into Bigfoot's ecosystem. Bigfoot plans to use recent financing to support ongoing product development, clinical trials, and commercialization of its Class III investigational systems. The company reported completing a $55 million Series B and has raised over $90 million in equity to date. Bigfoot is based in Milpitas, California.

Participated · Series D · Sep 2011

AM-Pharma B.V. is a clinical-stage biopharmaceutical company developing recAP, a recombinant human alkaline phosphatase therapeutic for acute kidney injury (AKI), particularly sepsis-associated AKI (SA-AKI). recAP has Fast Track designation from the U.S. FDA (awarded in 2016) and the company completed a 301-patient Phase II trial. The planned multinational pivotal Phase III trial aims to enroll up to 1,400 SA-AKI patients at sites in approximately 12 countries. Recent financing is intended to support that Phase III trial and to fund Marketing Authorization Application readiness activities, including CMC validation and commercial manufacture. AM-Pharma has raised additional capital bringing recent fundraising to a total of €163m, enabling the company to advance recAP toward registration and commercialization. The company's investor syndicate includes Cowen Healthcare Investments, the European Investment Bank and earlier backers such as LSP, Andera Partners, Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare. AM-Pharma is a clinical-stage biopharmaceutical company focused on recAP, a recombinant human alkaline phosphatase therapeutic for acute kidney injury (AKI). recAP is a proprietary recombinant human AP constructed from two human isoforms with a dual mechanism of action: dephosphorylation of lipopolysaccharides (LPS) and extracellular ATP to reduce inflammation and protect the kidney. The candidate reported promising Phase II STOP-AKI results in 301 sepsis patients, including a relative reduction in mortality of more than 40% and significant long-term kidney-function improvements; results were published in JAMA. The programme holds FDA Fast Track designation (2016) and the company is preparing a pivotal Phase III study in sepsis-associated AKI to enroll about 1,400 patients across approximately 12 countries. AM-Pharma plans to submit market-authorization applications in the US and Europe following successful completion of the single pivotal Phase III trial. The company is also exploring recAP in other indications including ulcerative colitis, necrotizing enterocolitis and hypophosphatasia. Financially, AM-Pharma has raised over €195m in equity and debt to date and recently secured €116m to support its Phase III programme. AM-Pharma, based in Bunnik, the Netherlands, focuses on the preclinical and clinical development of recombinant human Alkaline Phosphatase (recAP) as a treatment for inflammatory diseases. Its lead program is recAP for acute kidney injury (AKI) related to sepsis; the company also intends development for ulcerative colitis and hypophosphatasia and may pursue an oral formulation for UC. recAP is produced by cGMP manufacture for clinical trials and potential commercialization. Results from the current Phase II trial in AKI were expected in the second half of 2016. AM-Pharma built on positive Phase II data with bovine AP to develop the recombinant human form for future trials and commercialization. Since inception the company has raised €67 million from a syndicate of international investors and completed a €12.2 million financing in September 2014 to support the Phase II study and oral formulation work. AM-Pharma develops recAP, a proprietary recombinant human Alkaline Phosphatase optimized as an injectable for Acute Kidney Injury (AKI) and an oral formulation for Ulcerative Colitis (UC). The company plans to complete a 290‑patient, four‑arm, Phase II dose‑finding, placebo‑controlled, Phase III‑enabling study in AKI and to start Phase II development in UC. Proceeds from the recent financing will also support continued development of an oral recAP formulation. AM-Pharma bases its development on prior positive Phase II results with bovine Alkaline Phosphatase and manufactures recAP to cGMP standards for clinical supply. The company is headquartered in Bunnik, The Netherlands. Financially, AM-Pharma has previously raised €29.2M in Q4 2011 and has now closed an additional €12.2M financing to advance its clinical programs. AM-Pharma focuses on preclinical and clinical development of a human recombinant Alkaline Phosphatase (AP) as a protective treatment for severe inflammatory diseases. The company aims to replace bovine AP with its proprietary recombinant human AP for future trials and commercialization. Clinical proof-of-concept with bovine AP showed positive Phase II results in AKI and a Phase II trial in severe Ulcerative Colitis, supporting the development path. The current plan is to finalize GMP production of the recombinant AP and advance it through the end of Phase II. Management highlights the high unmet medical need in AKI, a market the article values at roughly USD 2 billion with over 700,000 annual deaths. AM-Pharma is based in Bunnik, The Netherlands.